While no significant correlation was observed between CD8+ TILs and relapse free survival (RFS) or overall survival (OS), patients with CD45RO+ infiltrating immune cells had longer relapse free survival and overall survival in cholangiocarcinoma (median RFS: 23.3 mo vs 12.5 mo, P = 0.006; median OS: 49.7 mo vs 18.9mo, P = 0.003) (Figure 2). Here, CD8A is linked to cholangiocarcinoma.